Pentavalent human-bovine reassortant rotavirus vaccine: A review of its efficacy and safety in preventing acute rotavirus gastroenteritis in healthy infants

Drugs of Today

Volumn 42, Issue 5, 2006, Pages 313-319

  Caple, Jane ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFUSION FLUID; LIVE VACCINE; ORAL REHYDRATION SOLUTION; PLACEBO; ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; CHILDHOOD MORTALITY; CLINICAL TRIAL; DERMATITIS; DEVELOPING COUNTRY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEVER; GENETIC REASSORTMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMATOCHEZIA; HUMAN; HUMAN ROTAVIRUS; IMMUNOGENICITY; INTUSSUSCEPTION; IRRITABILITY; MORBIDITY; NONHUMAN; ORAL REHYDRATION THERAPY; REVIEW; SEROTYPE; SIDE EFFECT; VIROLOGY; VIRUS INFECTION; VIRUS STRAIN; VOMITING;

GASTROENTERITIS; HUMANS; INFANT; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS; REASSORTANT VIRUSES; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 33745565320     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.5.973591     Document Type: Review

References (23)

1. Bresee, J.S., Glass, R.I., Ivanoff, B., Gentsch, J.R. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999, 17: 2207-22.
2. Parashar, U.D., Hummelman, E.G., Bresee, J.S., Miller, M.A., Glass, R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9: 565-72.
3. Murray, C.J., Lopez, A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349: 1436-42.
4. Jain, V., Parashar, U.D., Glass, R.I., Bhan, M.K. Epidemiology of rotavirus in India. Indian J Pediatr 2001, 68: 855-62.
5. Unicomb, L.E., Kilgore, P.E., Faruque, S.G. et al. Anticipating rotavirus vaccines: Hospital-based surveillance for rotavirus diarrhea and estimates of disease burden in Bangladesh. Pediatr Infect Dis J 1997, 16: 947-51.
6. Koopmans, M., Van Asperen, I. Epidemiology of rotavirus infections in the Netherlands. Acta Paediatr (Suppl.) 1999, 88: 31-7.
7. Ryan, M.J., Ramsay, M., Brown, D., Gay, N.J., Farrington, C.P., Wall, P.G. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis 1996, 174 (Suppl. 1): S12-8.
8. Jin, S., Kilgore, P.E., Holman, R.C., Clarke, M.J., Gangarosa, E.J., Glass, R.I. Trends in hospitalizations for diarrhea in United States children from 1979 through 1992: Estimates of the morbidity associated with rotavirus. Pediatr Infect Dis J 1996, 15: 397-404.
9. Tucker, A.W., Haddix, A.C., Bresee, J.S., Holman, R.C., Parashar, U.D., Glass, R.I. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998, 279: 1371-6.
10. Moulton, L.H., Staat, M.A., Santosham, M., Ward, R.L. The protective effectiveness of natural rotavirus infection in an American Indian population. J Infect Dis 1998, 178: 1562-6.
11. Velazquez, F.R., Matson, D.O., Calva, J.J. et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335: 1022-8.
12. Vethanayagam, R.R., Ananda Babu, M., Nagalaxmi, K.S. et al. Possible role of neonatal infection with the asymptomatic reassortant rotavirus (RV) strain 1321 in the decrease in hospital admissions for RV diarrhea, Bangalore, India, 1988-1999. J Infect Dis 2004, 189: 2282-9.
13. Gentsch, J.R., Woods, P.A., Ramachandran, M. et al. Review of G and P typing results from a global collection of rotavirus strains: Implications for vaccine development. J Infect Dis 1996, 174 (Suppl. 1): S30-6.
14. Santos, N., Hoshino, Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005, 15: 29-56.
15. Heaton, P.M., Goveia, M.G., Miller, J.M., Offit, P., Clark, H.F. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005, 192 (Suppl. 1): S17-21.
16. Clark, H.F., Offit, P.A., Ellis, R.W. et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996, 174 (Suppl. 1): S73-80.
17. Vesikari, T., Matson, D.O., Dennehy, P. et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354: 23-33.
18. Ruuska, T., Vesikari, T. Rotavirus disease in Finnish children: Use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22: 259-67.
19. Vesikari, T., Clark, H.F., Offit, P.A., Schodel, F. The effect of dose and composition of a pentavalent rotavirus reassortment vaccine (Rotateq™) upon efficacy and immunogenicity in healthy infants. 40th Annual Meeting of the Infectious Disease Society of America, Chicago 2002, Abst. 35.
20. Clark, H.F., Bernstein, D.I., Dennehy, P.H. et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004, 144: 184-90.
21. Murphy, T.V., Gargiullo, P.M., Massoudi, M.S. et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344: 564-72.
22. Vesikari, T., Clark, H.F., Offit, P.A., Schodel, F. The effect of dose and composition of a pentavalent rotavirus vaccine (Rotateq™) upon safety, efficacy, and immunogenicity in healthy infants. 22nd Annual Meeting of the European Society for Paediatric Infectious Diseases, Tampere 2004, Abst. 31.
23. Ward, R.L., Bernstein, D.I., Smith, V.E. et al. Rotavirus immunoglobulin A responses stimulated by each of three doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis 2004, 189: 2290-3.